Cognition at end of treatment · people with stroke
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Disability: mean scores at end of treatment (Analysis 1.10) · people with stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes adverse events: death ‐ at end of treatment Analysis 1.12 compared with placebo (very low certainty).
1 finding from 1 review
Medical interventions (systemic: analgesics, antidepressants, antiepileptics, steroids; topical: analgesics, anaesthetics) vs Another intervention, or no intervention
Outcome not reported · Patients of any age in any setting requiring intervention for iatrogenic injury to the inferior alveolar or lingual nerve
The review found no eligible studies for this question.
1 finding from 1 review
Results: 'No studies evaluated medical ... interventions.' No eligible RCT of medical interventions (analgesics, antidepressants, antiepileptics, steroids, topical anaesthetics).
0 studies
No studies found
Mean change in pain from baseline (0‐ to 10‐point scale, 0 is no pain) at 8–16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in pain from baseline (0‐ to 10‐point scale, 0 is no… compared with placebo (high certainty).
1 finding from 1 review
At least 50% reduction in pain · predominantly knee osteoarthritis
Antidepressant leads to higher responder rate: ≥ 50% reduction in 24‐hour mean pain compared with placebo (high certainty).
1 finding from 1 review
Physical function · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in physical function from baseline (0–100 WOMAC Total… compared with placebo (high certainty).
1 finding from 1 review
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants who withdrew due to adverse events between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher proportion of participants who withdrew due to adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Treatment success (caries lesion arrest or restoration survival) · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in treatment success compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
Antidepressant showed no clear difference in improvement in depression: HAM‐D score at 6‐12 weeks (dichotomized) compared with placebo (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
Antidepressant showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with placebo (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
Antidepressant showed no clear difference in study dropouts at 6‐12 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether antidepressant changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life score at 8 weeks · adults living with HIV and depression
1 finding from 1 review